Slides
Page 1
Sysmex Business Results First Three Months of the Fiscal Year Ending March 31 , 2027 Sysmex Corporation August 7 , 2026 Together for a better healthcare journey
Page 2
Disclaimer ・This material contains forward-looking statements about the Sysmex Group. These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements. ・The information on products and other matters contained herein is not intended as advertising or medical advice, whether or not regulatory approval has been obtained. ・The Sysmex Group adopted International Financial Reporting Standards (IFRS) in the fiscal year ended March 31, 2017. Figures are disclosed in compliance with IFRS.
Page 3
Index 3 Business Results, First Three Months of the Fiscal Year Ending March 31, 2027 1. (Appendix) 2. Strategic Themes under the Mid-Term Management Plan3. Executive Summary 4. Financial Forecast for the Fiscal Year Ending March 31, 2027
Page 4
Executive Summary1.
Page 5
5 Executive Summary (First Three Months of the Fiscal Year Ending March 31, 2027: Year on Year) Net sales ¥130.6billion +23.6% YoY Operating profit ¥14.8billion +39.5 % YoY Profit attributable to owners of the parent ¥8.6billion +90.9% YoY Strong growth in the Americas and yen depreciation drove substantial increases in sales and profits. Key reasons for higher sales Significant growth in the hematology field, centered on the Americas Solid growth in the EMEA and AP regions, helped by the impact of yen depreciation (On a local currency basis) ■Americas +26.1% / EMEA +11.0% / AP +7.6%* *Year-on-year change on a yen basis, excluding the impact of exchange rate fluctuations ■China - 33.8%, in line with initial forecast Net sales: +¥11.61 billion (+12.6%); SG&A expenses: +¥3.32 billion (+2.6%); operating profit: ¥+0.46 billion (+35.1%) Forex impact* Year-on-year change excluding foreign exchange effects is shown in parentheses. Key reasons for higher profits Higher gross profit resulting from increased sales, together with the elimination of one-time factors from the previous fiscal year (inventory revaluation) contributed to the increase in profit. Cash generation*Year-on-year change is shown in parentheses. Cash flows from operating activities: ¥35.5 billion (+ ¥26.1 billion) Free cash flow: ¥17.0 billion (+ ¥19.6 billion)
Page 6
6 Executive Summary (Revised First-Half and Full-Year Forecasts for the Fiscal Year Ending March 31, 2027) Net sales ¥265.0 billion Operating profit ¥25.0billion Profit attributable to owners of the parent ¥15.0billion We revised our first-half forecast upward in light of strong business progress in the Americas. For the second half, we have maintained our initial forecast. First-half forecast (revised) Net sales ¥545.0billion Operating profit ¥60.0 billion Profit attributable to owners of the parent ¥37.0 billion Full-year forecast (revised) vs. initial forecast: +¥10.0 billion YoY: +14.0% vs. initial forecast: +¥2.0 billion YoY: -24.1% vs. initial forecast: +¥1.0 billion YoY: -21.1% vs. initial forecast: +¥10.0 billion YoY: +9.0% vs. initial forecast: +¥2.0 billion YoY: +15.8% vs. initial forecast: +¥1.0 billion YoY: +4.4% In addition to strong business progress in the Americas, the positive impact of yen depreciation in Q1 is contributing to results. The forecast includes the possibility of one-time expenses in the Q2 related to business reviews and other factors. The initial forecast for the second half remains unchanged. - The forecast may be revised, if necessary, once the impact of new regulation in China and the business portfolio review becomes clearer.
Page 7
Business Results, First Three Months of the Fiscal Year Ending March 31, 2027 2.
Page 8
8 First three months of fiscal year ending March 31, 2027 First three months of fiscal year ended March 31, 2026 YoY (Previous period = 100%) Results Ratio Results Ratio Net sales 130.6 100% 105.7 100% 123.6% Cost of sales 64.3 49.3% 51.2 48.5% 125.5% SG&A expenses 42.6 32.6% 38.2 36.2% 111.3% R&D expenses 7.2 5.5% 6.4 6.1% 112.5% Other income (expenses) (1.6) - 0.8 0.8% - Operating profit 14.8 11.3% 10.6 10.1% 139.5% Profit attributable to owners of the parent 8.6 6.7% 4.5 4.3% 190.9% Financial Highlights (Year on Year) (Billions of yen) 86.0 95.3 111.9 105.7 130.6 11.0 13.2 16.7 10.6 14.8 8.0 8.6 11.0 4.5 8.6 2023 2024 2025 2026 2027 Net sales Operating profit Profit attributable to owners of the parent (Billions of yen) Q1 of fiscal year ending March 31, 2027 Q1 of fiscal year ended March 31, 2026 1USD ¥159.3 ¥144.6 1EUR ¥185.3 ¥163.8 1CNY ¥23.4 ¥20.0 (First three months of years to March 31)
Page 9
9 Breakdown of Net Sales (By Business and Field) First three months of fiscal year ending March 31, 2027 YoY (Previous period = 100%) Results Ratio Yen basis Excluding FX impact Excluding China and FX impacts Net sales 130.6 100.0% 123.6% 112.6% 121.6% Hematology 80.2 61.4% 123.8% 112.1% 115.5% FCM 1.5 1.2% 251.4% 225.5% 180.7% Urinalysis 11.0 8.5% 113.6% 102.2% 107.4% Hemostasis 14.6 11.2% 99.5% 90.9% 138.0% Immunochemistry 5.2 4.0% 129.8% 121.5% 165.3% Clinical chemistry 3.8 2.9% 596.1% 591.9% 678.2% Life science 6.5 5.1% 129.1% 118.4% 117.8% Others 6.6 5.0% 127.3% 116.2% 116.3% Diagnostics business 129.7 99.3% 123.8% 112.7% 121.8% Medical robotics business 0.9 0.7% 102.9% 102.7% 103.3% (Billions of yen) Sales by Business and Field +¥24.9 billion 2026 2027 (Billions of yen) Hemostasis Urinalysis Immuno- chemistry OthersLS FX impact Hematology FCM Medical robotics Clinical chemistry 105.7 7.85 0.20 -1.33 0.86 3.17 0.93 0.84 0.02 11.61 13.06 First three months of years to March 31 0.75
Page 10
10 2026 Instruments Reagents Services Others FX impact 2027 Breakdown of Net Sales (By Destination and Product Type) Americas • Favorable business performance continued, centered on North America and Brazil. Sales increased substantially, with growth across the hematology, hemostasis, and immunochemistry fields. EMEA • Double-digit growth in major countries drove solid expansion across key fields, including hematology, hemostasis, and urinalysis, resulting in higher sales. China • Sales declined due to the continuing impact of healthcare cost control policies that became apparent from Q2 of the previous fiscal year and distributor inventory adjustments. Results remained in line with the initial forecast. AP • In addition to strong growth in India, a recovery in Indonesia contributed to higher sales. Japan • Sales of both instruments and reagents returned to usual levels. The clinical chemistry business we acquired in April also contributed, resulting in a substantial increase in sales. Instruments 29.4 22.5% 151.6% 138.2% Reagents 75.9 58.1% 113.7% 103.2% Services 18.1 13.9% 116.2% 105.9% Others 7.2 5.5% 82.1% 171.7% Major Reasons for Changes by Destination Note: On a local currency basisFirst three months of fiscal year ending March 31, 2027 YoY (Previous period = 100%) Results Ratio Yen basis Local currency basis Net sales 130.6 100.0% 123.6% 112.6% Americas 41.9 32.1% 138.9% 126.1% EMEA 44.1 33.8% 125.5% 111.0% China 13.3 10.2% 77.5% 66.2% AP 13.8 10.6% 114.2% 107.6% Japan 17.3 13.3% 157.9% - (Billions of yen) By Product Type (Billions of yen) * * * * * * *Year-on-year change on a yen basis, excluding the impact of exchange rate fluctuations Substantial increase in net sales, driven by growth in the Americas, EMEA, AP, and Japan, together with the positive impact of yen depreciation By Destination 2026 Americas EMEA China AP Japan FX impact 2027 105.7 7.71 4.12 -5.81 0.92 6.38 11.61 130.6 (First three months of years to March 31) (First three months of years to March 31) 105.7 130.6 7.42 2.15 0.91 2.83 11.61 (Billions of yen)
Page 11
11 Information by Destination (Americas) Reagents Instruments Services, others (Million USD) First three months of fiscal year ending March 31, 2027 First three months of fiscal year ended March 31, 2026 YoY (Previous period = 100%) Local currency basis Yen basis Net sales 263.3 208.9 126.1% 138.9% Instruments 80.8 41.5 194.7% 214.6% Reagents 115.4 106.6 108.3% 119.3% Services, others 67.0 60.7 110.4% 121.7% Sales (Million USD) 83.9 91.9 102.9 106.6 115.4 45.3 52.4 43.2 41.5 80.849.0 52.4 56.8 60.7 67.0 178.2 196.7 202.9 208.9 263.3 2023 2024 2025 2026 2027 Instruments Sales increased significantly, led by strong performance in the hematology and hemostasis fields, particularly in North America. In the hematology field, progress in installing XN - Series units ordered in North America drove sales growth. Reagents Sales increased across all fields, supported by growth in the installed base of instruments, particularly in the hematology, urinalysis, and hemostasis fields. Sales of amyloid β testing reagents also remained strong. (Sales: USD 2.3 million) Favorable business performance continued, centered on North America and Brazil. Sales increased substantially, with growth across the hematology, hemostasis, and immunochemistry fields. (First three months of years to March 31)
Page 12
12 Information by Destination (EMEA) First three months of fiscal year ending March 31, 2027 First three months of fiscal year ended March 31, 2026 YoY (Previous period = 100%) Local currency basis Yen basis Net sales 238.1 214.6 111.0% 125.5% Instruments 57.5 47.2 121.9% 137.9% Reagents 144.6 134.4 107.6% 121.7% Services, others 35.8 32.9 108.8% 123.3% Reagents Instruments Services, others Instruments Sales of the XR -Series grew in France and Austria, and performance in the urinalysis field was favorable in Germany and Italy. In the hemostasis field, sales increased steadily across countries, centered on Germany and Italy. Reagents Sales increased, driven by growth in the installed base of instruments in major fields, including hematology. In the hemostasis field, sales also increased in Germany, where we won major tenders in the previous fiscal year, as well as in Saudi Arabia and other countries. (Million EUR) Sales (Million EUR) 102.7 117.6 131.9 134.4 144.6 50.4 43.8 41.9 47.2 57.529.4 30.8 32.9 32.9 35.8 182.5 192.5 206.8 214.6 238.1 2023 2024 2025 2026 2027 Double-digit growth in major countries drove solid expansion across key fields, including hematology, hemostasis, and urinalysis, resulting in higher sales. Note: Sales in Russia have been excluded, including for past years. (First three months of years to March 31)
Page 13
13 First three months of fiscal year ending March 31, 2027 First three months of fiscal year ended March 31, 2026 YoY (Previous period = 100%) Local currency basis Yen basis Net sales 571.6 864.0 66.2% 77.5% Instruments 33.9 87.6 38.8% 45.4% Reagents 474.5 702.9 67.5% 79.1% Services, others 63.0 73.3 85.9% 100.7% Information by Destination (China) (Million CNY) Instruments Sales declined as distributors continued to adjust inventories amid growing concerns over the expansion of healthcare cost control policies. Reagents Sales declined, mainly in the hemostasis field, due to the impact of the principle of minimal necessity. Sales declined, as distributors continued to adjust inventories, particularly in the hematology field. The impact of the standardization of testing prices has not yet become apparent. Sales declined due to the continuing impact of healthcare cost control policies that became apparent from Q2 of the previous fiscal year and distributor inventory adjustments. 554 646 720 702 474 121 126 97 87 33 67 81 89 73 63 742 854 908 864 571 2023 2024 2025 2026 2027 Reagents Instruments Services, others Sales (Million CNY) (First three months of years to March 31)
Page 14
14 -4.9% -24.9% -21.1% -38.5% -33.8% -24.0% -10.0% FY3/26 Q1 FY3/26 Q2 FY3/26 Q3 FY3/26 Q4 FY3/27 Q1 FY3/27 Q2 FY3/27 2H Distributor inventory adjustments Principal of minimal necessity Other factors (VBP, competition, etc.) Impact of testing price standardization Overall impact (%) China: Current Situation and Outlook for the Future Q1 results remained inline with initial forecast and we maintained our initial full-year forecast YoY Change in Sales (Previous period = 100%)(Conceptual) 0 FY3/26 (Full Year): -25% (Local Currency Basis) Organic growth + portfolio expansion, etc. (pt) FY3/27 (Full Year): -20% (Local Currency Basis) Q1 Results for the Fiscal Year Ending March 31, 2027: As Expected • The impacts of the principle of minimal necessity and distributor inventory adjustments continued. Outlook for the Fiscal Year Ending March 31, 2027 1H: We expect Q2 performance to also remain within the range assumed in the initial forecast. 2H: We expect the principle of minimal necessity to run its course There is a risk that distributor inventory adjustments may continue (instruments). The impact of the standardization of testing prices is expected to expand nationwide from Q4, but the situation remains uncertain. We will closely monitor developments and disclose any significant changes in a timely manner.
Page 15
15 Second Round of Public Consultation on the Standardization of Testing Prices Testing prices are not expected to be standardized nationwide at a single minimum price. Rather, pricing is expected to be determined by each province, taking regional characteristics and developments in the pilot provinces into account. Following publication of the final version, reagent prices are expected to decline. However, pricing levels have not yet been disclosed, and the impact on the Company’s business performance remains uncertain. June 30 announcement (first round closed at the endo of March) ・Additional public consultation on testing parameters and pricing ・Soliciting feedback from hospitals, companies, industry associations, and other stakeholders Comment submission deadline of July 6 ・Approximately 50 proposed additions and revisions in total Outlook July–August End of August September–December Pilot implementation in six provinces across four regions Publication of the final version and implementation details Nationwide rollout period
Page 16
16 First three months of fiscal year ending March 31, 2027 First three months of fiscal year ended March 31, 2026 YoY(Previous period = 100%) Yen basis Net sales 13.8 12.0 114.2% (107.6%) Diagnostics business 13.7 12.0 114.2% Instruments 1.7 2.3 74.9% Reagents 11.0 8.6 127.7% Services, others 0.9 1.0 90.2% Medical robotics business 0.03 0.04 92.0% Information by Destination (AP) In addition to strong growth in India, a recovery in Indonesia contributed to higher sales. (Billions of yen) Note: Figures in parentheses exclude the impact of exchange rate fluctuations. Sales (Billion JPY) Diagnostics business Instruments Sales declined due to delays in tender awards in India and the Philippines, among other factors. Reagents In India, sales increased substantially, driven by growth in the installed base of instruments in the hematology, urinalysis, and hemostasis fields. Sales were favorable, particularly in Southeast Asia, including Singapore and Malaysia, resulting in higher sales across all fields. Medical robotics business Obtained marketing approval in Vietnam. Reagents Instruments Services, others 5.5 6.8 8.4 8.6 11.0 1.9 2.0 2.5 2.3 1.7 0.7 0.8 1.3 1.0 0.9 8.1 9.7 12.3 12.0 13.8 2023 2024 2025 2026 2027 (0.4) (0.6) *( ) indicate sales in Russia *Sales in Russia excluded * Sales in Russia included (0.9) (1.1) (First three months of years to March 31)
Page 17
17 9.0 8.8 8.6 6.6 8.5 1.4 1.7 1.6 1.5 1.6 1.9 2.1 2.2 1.9 2.9 3.4 0.5 0.2 1.1 0.8 0.8 2023 2024 2025 2026 2027 Diagnostics business Instruments Sales declined in the hematology field after replacement demand ran its course. Reagents Sales increased as the number of tests grew, supported by an expanded installed base of instruments in the urinalysis, hemostasis, and immunochemistry fields. The temporary decrease in the previous years due to system transition eased off. Business acquisition Operations started in April, contributing to sales growth in the clinical chemistry and immunochemistry fields. Medical robotics business • Installations during the first quarter: 2 units (cumulative installed base: 108 units) Information by Destination (Japan) First three months of fiscal year ending March 31, 2027 First three months of fiscal year ended March 31, 2026 YoY(Previous period = 100%) Yen basis Net sales 17.3 11.0 157.9% Diagnostics business 16.4 10.1 162.6% Instruments 3.0 1.5 194.8% Reagents 8.5 6.6 129.0% Services, others 4.9 1.9 249.6% Medical robotics business 0.8 0.8 103.4% Sales of both instruments and reagents returned to typical levels. The clinical chemistry business we acquired in April also contributed, resulting in a substantial increase in sales Sales (Billion JPY) (Billions of yen) Medical robotics business Reagents Instruments Services, others Sales from acquired business 17.3 11.0 13.713.012.9 (First three months of years to March 31)
Page 18
18 2026.3 1Q 売上変動による粗利変動 前年度特殊要因の影響 原価率の変動 販管費の増加 研究開発費の減少 その他営業損益の変動 為替の影響 2027.3 1Q Increase in gross profit due to higher sales: +¥6.86 billion Absence of the prior-year impact of inventory revaluation: +¥1.75 billion Change in the cost of sales ratio: -¥0.71 billion (0.5pt deterioration) Positive factor: Higher sales of high-margin instruments, 1.6 pt Negative factors: Product mix, 3.2 pt, Tariff impact, 0.2 pt Increase in SG&A expenses: -¥0.99 billion Personnel expenses: -¥0.5 billion due to workforce expansion associated with the expansion of direct sales regions and higher unit labor costs Increase in R&D expenses: -¥0.8 billion Expanded investment in product development Change in other operating income and expenses: -¥2.38 billion A provision was recorded for potential losses associated with contractual obligations Breakdown of Operating Profit (Year on Year) Note: Figures and comments below exclude the impact of exchange rates. FX impact: +¥0.46 billion Operating profit (Billions of yen) FX impact +¥4.1 billion 2026 2027 Higher SG&A expenses Increased gross profit on higher sales Higher R&D expenses Change in other income and expenses Change in the cost of sales ratio Absence of the prior- year inventory revaluation impact (First three months of years to March 31) 10.6 14.8 6.86 1.75 -0.71 -0.99 -0.80 -2.38 0.46
Page 19
Strategic Themes under the Mid-Term Management Plan 3.
Page 20
20 1,106 1,119 1,358 5,122 5,327 7,000 2025 2026 2027 Progress on Strategic Themes Q1 results (local currency basis), YoY: +41% • Activities built on the existing hematology customer base are bearing fruit, with growth in both instruments and reagents. • We are strengthening competitiveness through measures such as obtaining regulatory approval for special-assay reagents, including HIT IgG reagents. EMEA Americas Q1 results (local currency basis), YoY: +134% • North America: Started installation of the CN -Series. We will strengthen sales activities to secure large-scale projects going forward. • Central and South America: We have obtained regulatory approval for the CN-Series in Brazil. Sales are scheduled to begin in Q2 of the fiscal year ending March 31, 2027. Accelerate Expansion in the Hemostasis Field Expansion in Emerging Markets 7.9 7.8 9.3 3.7 3.1 3.7 5.3 4.7 6.1 16.9 15.6 19.1 2025 2026 2027 Asia Central and South America Middle East and Africa Brazil India (Million INR) (Billions of yen) ■Sales (Q1) 8.7 7.0 9.9 32 36 43 2025 2026 2027 Q1 1Q (Million USD) ＋41% ＋21% Emerging Markets (Asia, Central and South America, Middle East, Africa) ＋22% Favorable growth in the hematology and urinalysis fields Developing new products to meet Indian market demand Steady growth in each region (Years to March 31) (Years to March 31) (Years to March 31) Full Year Full Year
Page 21
21 Progress on Initiatives to Improve Profitability Value Chain Reform Improving Reagent Profitability • A Company-wide project is underway to improve reagent costs and accelerate initiatives to enhance profitability. We will improve profitability and capital efficiency through the twin pillars of value chain reform and utilizing digital technologies Immunochemistry field ・Promoting reductions in production frequency and the in-house production of raw materials, centered on infectious disease testing parameters such as HBV and HCV, through production scale-up →Although the scale of the business is limited, reagent costs are higher than in other fields, leaving substantial room for improvement. Improving Productivity through AI and Digital Technologies • Leveraging globally accumulated operational data to drive business transformation aimed at improving profitability and efficiency. Operational Data Benchmarks Internal Analysis & Peer Benchmarking Detailed analysis of order receipt, shipment, invoicing, and payment processes Identified factors behind extended shipment lead times and manual operations Shortening lead time from order receipt to shipment Initiated standardization and automation of customer order processing Transition to the execution phase Internal data A High-productivity corporate structure Key initiatives: Hematology field ・Reviewing raw materials and manufacturing processes for reagents such as staining and hemolysis reagents, and promoting optimization initiatives →Although the gross margin is already high and the scope for improvement is limited, meaningful benefits are expected given the scale of the business.
Page 22
Financial Forecast for the Fiscal Year Ending March 31, 2027 4.
Page 23
23 Revised Financial Forecast for the Fiscal Year Ending March 31, 2027 (First Half) Q1 of fiscal year ending March 31, 2027 (April–June) Q2 of fiscal year ending March 31, 2027 (July–September) Announced forecast for first six months of fiscal year ending March 31, 2027 (April – September) Results Ratio Forecast Ratio revised Ratio YoY (Previous period = 100%) vs. initial forecast Net sales 130.6 100% 134.3 100% 265.0 100.0% 114.0% +10.0 Cost of sales 64.3 49.3% 64.6 48.1% 129.0 48.7% 117.3% +2.0 SG&A expenses 42.6 32.6% 47.4 35.3% 90.0 34.0% 115.6% ±0.0 R&D expenses 7.2 5.5% 7.8 5.8% 15.0 5.7% 113.6% ±0.0 Other income (expenses) (1.6) - (4.3) - (6.0) - - (6.0) Operating profit 14.8 11.3% 10.2 7.6% 25.0 9.4% 75.9% +2.0 Profit attributable to owners of the parent 8.6 6.7% 6.3 4.7% 15.0 5.7% 78.9% +1.0 (Billions of yen) Green indicates changes from the previous forecast (announced in May 2026). Q1 of fiscal year ending March 31, 2027 (April–June) (Results) Q2 of fiscal year ending March 31, 2027 (July–September) (Unchanged) 1H (Revised August 2026) 1 USD ¥159.3 ¥155.0 ¥157.2 1 EUR ¥185.3 ¥180.0 ¥182.6 1 CNY ¥23.4 ¥22.0 ¥22.7 Exchange Rates (Actual/Assumed)
Page 24
24 23.0 3.4 0.6 1.2 2.28 △ 2.28 △ 4.5 1.3 25.0 255.0 5.3 0.9 3.8 265.0 上期期初想定 米州 その他地域 為替の影響 上期上方修正 Net Sales Operating Profit (Billions of yen) Revised Financial Forecast for the First Half of the Fiscal Year Ending March 31, 2027 (Billions of yen) Government subsidies in China Americas FX impact Announced May 2026 Revised August 2026 Increased gross profit on higher sales Optimization of SG&A expenses Improved cost of sales ratio Increase in other operating losses FX impact +¥2.0 billion+¥10.0 billion Potential one- time expenses from business reviews Other Regions Announced May 2026 Revised August 2026
Page 25
25 Revised Financial Forecast for the Fiscal Year Ending March 31, 2027 (Full Year) 2H of fiscal year ending March 31, 2027 (October–March) Full-year forecast for fiscal year ending March 31, 2027 (April–March) Forecast Ratio revised Ratio Year on year vs. initial forecast Net sales 280.0 100% 545.0 100.0% 109.0% +10.0 Cost of sales 140.0 50.0% 269.0 49.4% 110.1% +2.0 SG&A expenses 91.0 32.5% 181.0 33.2% 110.1% ±0.0 R&D expenses 15.0 5.4% 30.0 5.5% 102.9% ±0.0 Other income (expenses) 1.0 0.4% (5.0) - - (6.0) Operating profit 35.0 12.5% 60.0 11.0% 115.8% +2.0 Profit attributable to owners of the parent 22.0 7.9% 37.0 6.8% 104.4% +1.0 (Billions of yen) Assumed Exchange Rates Exchange Rate Sensitivity* *Impact of a ¥0.1 change in the exchange rate Net sales Operating profit USD ¥0.87 billion ¥0.22 billion EUR ¥0.64 billion ¥0.07 billion CNY* ¥0.33 billion ¥0.24 billion 1H (Revised Aug. 2026) 2H (Unchanged) Full year (Revised Aug. 2026) 1 USD ¥157.2 ¥155.0 ¥156.1 1 EUR ¥182.6 ¥180.0 ¥181.3 1 CNY ¥22.7 ¥22.0 ¥22.4 Full-year forecast ROE 7.5% ROIC 7.5% CCC 200 days Operating cash flow ¥89.0 billion Free cash flow ¥28.0 billion Green indicates changes from the previous forecast (announced in May 2026). Planned investment（Unchanged）：Capital expenditure ¥48.0 billion, Depreciation and amortization ¥47.0 billion
Page 26
26 Revised Forecast for the Fiscal Year ending March 31, 2027 (Sales by Business, Field, and Destination) ■Sales by destination Fiscal year ending March 31, 2027 Ratio YoY (Previous period = 100%) Hematology 325.0 59.6% 108.5% FCM 7.5 1.4% 159.9% Urinalysis 49.0 9.0% 111.2% Hemostasis 74.0 13.6% 102.2% Immunochemistry 23.0 4.2% 103.1% Clinical chemistry 13.0 2.4% 445.7% Life science 24.0 4.4% 96.2% Others 24.0 4.4% 92.5% Diagnostics business 539.5 99.0% 108.6% Medical robotics business 5.5 1.0% 166.5% Total 545.0 100% 109.0% Fiscal year ending March 31, 2027 Ratio YoY (Previous period = 100%) Yen basis Local currency basis Americas 158.5 29.1% 113.8% 110.1% EMEA 176.0 32.3% 111.4% 107.6% China 76.5 14.0% 85.5% 81.8% AP 62.0 11.4% 113.5% - Japan 72.0 13.2% 122.9% - ■Sales by business and field (Billions of yen)(Billions of yen) Green indicates changes from the previous forecast (announced in May 2026).
Page 27
(Appendix)
Page 28
28 Sustainability Targets Results for the Fiscal Year Ended March 31, 2026 Creating value for a healthy society Materiality KPI Results Targets Fiscal year ended March 31, 2025 Fiscal year ended March 31, 2026 Fiscal year ending March 31, 2027 Improving the quality of life of each individual and extending healthy life expectancy Improving the safety and productivity of healthcare professionals Improving healthcare economics Improvement in accessibility to healthcare Number of hematology tests 2,904 million *1 3,014 million - Hematology market share*2 56.0%*1 56.1% - Number of cases with surgical support robot 5,209 7,857 - Number of patents 3,337 2,931 - Number of new patents 182 173 - Number of patent genomes analyzed*3 1.8 thousand 1.7 thousand - Number of breast cancer tests using the OSNA method 53 thousand 53 thousand - Sales in emerging and developing markets*4 ¥179.5 billion ¥157.4 billion - Providing responsible products, services, and solutions Materiality KPI Results Targets Fiscal year ended March 31, 2025 Fiscal year ended March 31, 2026 Fiscal year ending March 31, 2027 Pursuit of quality and trust Number of recalls 6 6 - Number of FDA warning letters 0 0 - Maintaining stable supply through the development of a resilient supply chain CSR survey response rate (primary suppliers in Japan and overseas) 95% 95% 90% Number of training sessions for suppliers (Japan) *5 6 6 3 Third-party certification rate of suppliers (primary, Japan) *5 89% 90% - *1 The previous year’s figure has been revised, owing to a change in calculation method. *2 Source: Clearstate and Sysmex’s assumptions *3 Target: Sysmex Group in Japan *4 :including China *5 Target: Sysmex Corporation on a non-consolidated basis ・The items whose targets are displayed as “-” are monitoring items for which no targets are set.
Page 29
29 Sustainability Targets Results for the Fiscal Year Ended March 31, 2026 Reducing environmental impacts Materiality KPI Results Targets Fiscal year ended March 31, 2025 Fiscal year ended March 31, 2026 Fiscal year ending March 31, 2027 Resource circulation in product life cycle Zero product losses 0.40% 0.18% 0.16% Recycling of containers and packing and utilization of environment compliance materials 62% 67% 70% Reduction of greenhouse gas emissions (Scope 3) *1 Cut 1% Up 8% Cut 7％ Supplier engagement ratio 40% 40% ー Reduction of packaging and labeling materials*2 Cut 4％ Cut 25％ ー Responding to climate change Efficient use of water resources Reduction of greenhouse gas emissions (Scopes 1, 2)*1 Cut 33% Cut 41% Cut 44％ Ratio of renewable energy 72% 83% 82％ Reduction of using energy per employee*1 Cut 7% Cut 17% ー Reduction of water consumption (main reagent factories)*1 Cut 31pt Cut 25pt Cut 34pt Reduction of total waste*1 Cut 33％ Cut 41％ Cut 43％ Ratio of product waste to sales 0.5% 0.3% ― Scope 1: GHG emitted directly by company facilities, factories, and fleet Scope 2: GHG emitted indirectly by the company due to energy use Scope 3: GHG emitted throughout the value chain in relation to products and services *1 Base year: Fiscal year ended March 31, 2023 *2 Base year: Fiscal year ended March 31, 2020 ・The items whose targets are displayed as “-” are monitoring items for which no targets are set.
Page 30
30 Sustainability Targets Results for the Fiscal Year Ended March 31, 2026 Strengthening governance Materiality KPI Results Targets Fiscal year ended March 31, 2025 Fiscal year ended March 31, 2026 Fiscal year ending March 31, 2027 Business activities based on legal compliance, respect for human rights, and high ethical standards Cybersecurity measures for information systems and products Number of meetings with investors and analysts *2 753 901 - Number of internal reports 17 50 - Number of unethical incidents 19 26 - Number of information security trainees*1 27,060 31,744 - Participation rate in disaster drills*1 89.5% 88.6% - ・The items whose targets are displayed as “-” are monitoring items for which no targets are set. *1 Target: Sysmex Group in Japan *2 Target: Sysmex Corporation on a non-consolidated basis
Page 31
31 Sustainability Targets Results for the Fiscal Year Ended March 31, 2026 Maximizing human capital Materiality KPI Results Targets Fiscal year ended March 31, 2025 Fiscal year ended March 31, 2026 Fiscal year ending March 31, 2027 Talent acquisition and development Engagement score 76% 74% 75％ Turnover ratio 8.0% 8.0% 10% or less Self-turnover rate 5.6% 4.4% ー Return rate from parental leave*2 99% 100% ー Percentage of men taking childcare leave*2 77% 80% 70％ or more Promotion of diversity, equity & inclusion (DE&I) Female managers ratio 18.7% 19.7% 21% Female next-generation managers ratio 34.0% 34.2% ー Female employees rate 41.1% 41.4% ー Percentage of mid-career recruitment in managerial and professional positions*2 38.6% 37.8% ー Male/female percentage among recruits (new graduates and mid-career) *2 Newly graduated: 43.0% Mid-career: 36.5% Newly graduated: 37.5% Mid-career: 15.7% ー Percentage of women and non-Japanese nationals in management Women: 8.3% Non-Japanese: 16.7% Women: 12.0% Non-Japanese: 16.0% ー Percentage of women in management of group companies 14.8% 12.3% ー Salary inequality in managerial and professional positions (total compensation) *2 96.2% 95.4% ー Salary inequality general employees (total compensation) *2 84.7% 85.9% ー Percentage of employees with disabilities*1 2.69% 2.63% 2.7% or more ・The items whose targets are displayed as “-” are monitoring items for which no targets are set. *1 Target: Sysmex Group in Japan *2 Target: Sysmex Corporation on a non-consolidated basis
Page 32
32 Sustainability Targets Results for the Fiscal Year Ended March 31, 2026 Maximizing human capital Materiality KPI Results Targets Fiscal year ended March 31, 2025 Fiscal year ended March 31, 2026 Fiscal year ending March 31, 2027 Talent acquisition and development Training time per employee 24.7 hours 29.5 hours 40.0 hours Value-added productivity (non-consolidated)*2 ¥15,042 ¥11,230 ー Value-added productivity (Group) ¥21.44 million ¥19.01 million ¥21.00 million Human resources development investment (non-consolidated)*2 ¥261 million ¥222 million ー Human resources development investment (Group) ¥595 million ¥607 million ー Participation rate in training (non-consolidated) *2 100% 100% 90% or more Participation rate in training (Group) 96% 97.60% ー Success plan effectiveness Rate*2 92.3% 100% ー Succession coverage rate*2 289.5% 218.2% ー Promotion of health and occupational safety Total annual working hours *1.. 1,993 hours 1,974 hours 1,980 hours Percentage of days of paid leave taken*1 67.1% 76.70% 75％ or more Lost-time injury frequency rate*1 0.83*3 0.56 Less than 0.5 Lost work day rate*1 0.05 0.04 Less than 0.05 ・The items whose targets are displayed as “-” are monitoring items for which no targets are set. *1 Target: Sysmex Group in Japan *2 Target: Sysmex Corporation on a non-consolidated basis *3 The previous year’s figure has been revised, owing to a change in calculation method